Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123929 | 0.82 | KDR (0.59) | TRPV1KMT2APRKCIKDRNPC1 | |
| SCHEMBL3115333 | 0.82 | KMT2A (0.46) | KMT2APRKCIKDRNPC1RAB9A | |
| SCHEMBL3110688 | 0.81 | RXFP1 (0.57) | KMT2AKDR | |
| SCHEMBL7134460 | 0.81 | KDR (0.64) | TRPV1KMT2APRKCIKDRNPC1 | |
| SCHEMBL3107870 | 0.81 | KDR (0.50) | TRPV1KDR | |
| SCHEMBL3118019 | 0.80 | KDR (0.60) | TRPV1KMT2APRKCIKDRNPC1 | |
| SCHEMBL3119139 | 0.79 | GRM4 (0.55) | TRPV1KMT2AKDR | |
| SCHEMBL3114991 | 0.79 | KDR (0.52) | TRPV1KMT2AKDR | |
| SCHEMBL3112582 | 0.78 | MAPT (0.49) | KMT2AKDRNPC1RAB9A | |
| SCHEMBL444553 | 0.78 | TRPV1 (0.60) | NAMPTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1259487-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | disclosed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | NAMPT 30/4885TRPV1 1662/4885KMT2A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.